Truist Securities Reiterates Buy on Praxis Precision Medicine, Maintains $150 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Joon Lee has reiterated a Buy rating on Praxis Precision Medicine (NASDAQ:PRAX) and maintained a $150 price target on the stock.
December 04, 2023 | 3:43 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities analyst Joon Lee reaffirmed a Buy rating on Praxis Precision Medicine with a $150 price target, indicating a positive outlook on the stock.
The reiteration of a Buy rating and the maintenance of a high price target by a reputable analyst like Joon Lee can instill confidence in investors and potentially lead to a short-term increase in the stock price of PRAX. The specific mention of the company and the price target suggests a strong conviction in the company's future performance.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100